Platelet activation, oxidative stress and overexpression of inducible nitric oxide synthase in moderate heart failure

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 10, 2011, Pages 705-710

  De Meirelles, Luisa R ^a   Resende, Angela de C ^a   Matsuura, Cristiane ^a   Salgado, Ângelo ^b   Pereira, Natalia R ^a   Cascarelli, Pedro G ^b   Mendes Ribeiro, Antônio C ^a,c   Brunini, Tatiana M C ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^c FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

Heart failure; Inflammation; l arginine; Nitric oxide; Oxidative stress; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; ARGININE; C REACTIVE PROTEIN; CITRULLINE; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OXIDATIVE STRESS; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

ADENOSINE DIPHOSPHATE; ARGININE; BLOOD PLATELETS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLLAGEN; FEMALE; FIBRINOGEN; HEART FAILURE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PLATELET ACTIVATION; PLATELET AGGREGATION; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 80053140318     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05580.x     Document Type: Article

References (35)

1. Chung I, Lip GYH. Platelets and heart failure. Eur. Heart J. 2006; 27: 2623-31.
2. American College of Cardiology/American Heart Association. Guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 2005; 112: 154-235.
3. McKelvie RS. Exercise training in patients with heart failure: Clinical outcomes, safety, and indications. Heart Fail. Rev. 2008; 13: 3-11.
4. Kothari HP, Patel S, Thohan V. Perioperative risk assessment among patients with congestive heart failure: A call for guidelines. Methodist Debakey Cardiovasc. 2009; 5: 2-8.
5. Ramani GV, Uber PA, Mehra MR. Chronic heart failure: Contemporary diagnosis and management. Mayo Clin. Proc. 2010; 85: 180-95.
6. Chung I, Lip GYH. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann. Med. 2009; 41: 45-51.
7. Chong AY, Chin BS, Blann AD, Lip GY. Effects of antiplatelet therapy and oral anticoagulation on indices of endothelial damage/dysfunction in patients with systolic heart failure in sinus rhythm. Thromb. Res. 2005; 116: 181-3.
8. Palmer RM, Rees DD, Ashton DS, Moncada S. l-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun.. 1988; 153: 1251-6.
9. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351: 714-18.
10. Moncada S. Adventures in vascular biology: A tale of two mediators. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2006; 361: 735-59.
11. Ignarro LJ. Heme-dependent activation of guanylate cyclase by nitric oxide: A novel signal transduction mechanism. Blood Vessels 1991; 28: 67-73.
12. Mendes-Ribeiro AC, Brunini TMC, Ellory JC, Mann GE. Abnormalities in l-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc. Res. 2001; 49: 697-712.
13. Hoobs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 191-220.
14. Mendes-Ribeiro AC, Mann GE, de Meirelles LR, Moss MB, Matsuura C, Brunini TMC. The role of exercise on l-arginine nitric oxide pathway in chronic heart failure. Biochem. J. 2009; 3: 55-65.
15. Brunini TMC, Resende AC, Moss MB et al. l-Arginine-availability as a pathological mechanism in essential hypertension. Vasc. Dis. Prev. 2005; 2: 37-51.
16. Ochs-Bacom HM, Grant BJB, Muti P et al. Oxidative stress and pulmonary function in the general population. Am. J. Epidemiol. 2005; 162: 1137-45.
17. Rohde LE, Belló-Klein A, Pereira RP et al. Superoxide dismutase activity in adriamycin-induced cardiotoxicity in humans: A potential novel tool for risk stratification. J. Cardiac Fail. 2005; 11: 220-5.
18. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ. J. 2006; 70: 1001-5.
19. Eleuteri E, Magno F, Gnemmi I et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front. Biosci. 2009; 1: 2230-7.
20. de Meirelles LR, Mendes Ribeiro AC, Mendes MA et al. Chronic exercise reduces platelet activation in hypertension: Upregulation of l-arginine-nitric oxide pathway. Scand. J. Med. Sci. Sports 2009; 19: 67-74.
21. Rodrigues Pereira N, Bandeira Moss M, Assumpção CR et al. Oxidative stress, l-arginine-nitric oxide and arginase pathways in platelets from adolescents with anorexia nervosa. Blood Cells Mol. Dis. 2010; 44: 164-8.
22. de Meirelles LR, Mendes-Ribeiro AC, Santoro MM et al. Inhibitory effects of endogenous l-arginine analogues on nitric oxide synthesis in platelets: Role in platelet hyperaggregability in hypertension. Clin. Exp. Pharmacol. Physiol. 2007; 34: 1267-71.
23. Sánchez-Lázaro IJ, Almenar L, Reganon E et al. Inflammatory markers in stable heart failure and their relationship with functional class. Int. J. Cardiol. 2008; 129: 388-93.
24. Freeman LM. The pathophysiology of cardiac cachexia. Curr. Opin. Support. Palliat. Care 2009; 3: 276-81.
25. Hanssen H, Brunini TMC, Conway M et al. Increased l-aginine transport in human erytrocytes in chronic heart failure. Clin. Sci. 1998; 94: 43-8.
26. Rector TS, Bank AJ, Mullen KA et al. Randomized, double-blind, placebo-controlled study of supplemental oral l-arginine in patients with heart failure. Circulation 1996; 93: 2135-41.
27. Hambrecht R, Hilbrich L, Erbs S et al. Correction of endothelial dysfunction in chronic heart failure: Additional effects of exercise training and oral l-arginine supplementation. J. Am. Coll. Cardiol. 2000; 35: 706-13.
28. Chin-Dusting JP, Kaye DM, Lefkovits J, Wong J, Bergin P, Jennings GL. Dietary supplementation with l-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J. Am. Coll. Cardiol. 1996; 27: 1207-13.
29. Brooks WW, Conrad CH, Robinson KG, Colucci WS, Bing OH. l-Arginine fails to prevent ventricular remodeling and heart failure in the spontaneously hypertensive rat. Am. J. Hypertens.. 2009; 22: 228-34.
30. Trachtenberg BH, Hare JM. Biomarkers of oxidative stress in heart failure. Heart Fail. Clin. 2009; 5: 561-77.
31. Sedar A, Yesibursa D, Sedar Z, Dirican M, Turel B, Cordan J. Relation of functional capacity with the oxidative stress and antioxidants in chronic heart failure. Congest. Heart Fail. 2001; 7: 309-11.
32. Chirkov YY, de Sciscio M, Sverdlov AL, Leslie S, Sage PR, Horowitz JD. Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure. Cardiovasc. Drugs Ther. 2010; 24: 131-7.
33. Rajendran S, Chirkov YY. Platelet hyperaggregability: Impaired responsiveness to nitric oxide ('platelet NO resistance') as a therapeutic target. Cardiovasc. Drugs Ther. 2008; 22: 193-203.
34. Ellis GR, Anderson RA, Chirkov YY et al. Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J. Cardiovasc. Pharmacol. 2001; 37: 564-70.
35. Anderson RA, Ellis GR, Chirkov YY et al. Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur. J. Heart Fail. 2004; 6: 47-54.